Premium
Bioprocess Engineering Issues That Would Be Faced in Producing a DNA Vaccine at up to 100 m 3 Fermentation Scale for an Influenza Pandemic
Author(s) -
Hoare Mike,
Levy M. Susana,
Bracewell Daniel G.,
Doig Steven D.,
Kong Simyee,
TitchenerHooker Nigel,
Ward John M.,
Dunnill Peter
Publication year - 2005
Publication title -
biotechnology progress
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.572
H-Index - 129
eISSN - 1520-6033
pISSN - 8756-7938
DOI - 10.1021/bp050190n
Subject(s) - bioprocess , pandemic , scale (ratio) , dna vaccination , domain (mathematical analysis) , biopharmaceutical , microbiology and biotechnology , risk analysis (engineering) , covid-19 , engineering , business , biology , immunization , medicine , infectious disease (medical specialty) , immune system , mathematical analysis , physics , disease , mathematics , pathology , quantum mechanics , chemical engineering , immunology
The risk of a pandemic with a virulent form of influenza is acknowledged by the World Health Organization (WHO) and other agencies. Current vaccine production facilities would be unable to meet the global requirement for vaccine. As a possible supplement a DNA vaccine may be appropriate, and bioprocess engineering factors bearing on the use of existing biopharmaceutical and antibiotics plants to produce it are described. This approach addresses the uncertainty of timing of a pandemic that precludes purpose‐built facilities. The strengths and weaknesses of alternative downstream processing routes are analyzed, and several gaps in public domain information are addressed. The conclusion is that such processing would be challenging but feasible.